Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

1279000

USP

Fluorouracil

United States Pharmacopeia (USP) Reference Standard

Synonyme(s) :

5-Fluorouracil, 2,4-Dihydroxy-5-fluoropyrimidine, 5-FU, 5-Fluoro-2,4(1H,3H)-pyrimidinedione

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C4H3FN2O2
Numéro CAS:
51-21-8
Poids moléculaire :
130.08
Numéro Beilstein :
127172
Numéro MDL:
MFCD00006018
Code UNSPSC :
41116107
ID de substance PubChem :
329749871
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

fluorouracil

Fabricant/nom de marque

USP

Pf

282-286 °C (dec.) (lit.)

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

FC1=CNC(=O)NC1=O

InChI

1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)

Clé InChI

GHASVSINZRGABV-UHFFFAOYSA-N

Informations sur le gène

human ... TYMS(7298)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Fluorouracil USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Flucytosine
  • Flucytosine Capsules
  • Fluorouracil
  • Fluorouracil Cream
  • Fluorouracil Injection
  • Fluorouracil Topical Solution

Remarque sur l'analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

F0250000

Fluorouracil, European Pharmacopoeia (EP) Reference Standard

Y0000762

Fluorouracil impurity A, European Pharmacopoeia (EP) Reference Standard

Y0000763

Fluorouracil impurity B, European Pharmacopoeia (EP) Reference Standard

Y0000791

Fluorouracil impurity mixture, European Pharmacopoeia (EP) Reference Standard

Y0000765

Fluorouracil impurity F, European Pharmacopoeia (EP) Reference Standard

Y0000764

Uracile, European Pharmacopoeia (EP) Reference Standard

1279054

Fluorouracil Related Compound E, United States Pharmacopeia (USP) Reference Standard

1279065

Fluorouracil Related Compound F, United States Pharmacopeia (USP) Reference Standard

1279019

Fluorouracil Related Compound A, United States Pharmacopeia (USP) Reference Standard

1279021

Fluorouracil Related Compound B, United States Pharmacopeia (USP) Reference Standard

BP995

Fluorouracil, British Pharmacopoeia (BP) Reference Standard

PHR2584

5,6-Diamino-1,3-dimethyluracil, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2865

Fluorouracil Related Compound A, certified reference material, pharmaceutical secondary standard

PHR2866

Fluorouracil Related Compound B, pharmaceutical secondary standard, certified reference material

PHR2867

Fluorouracil Related Compound E, certified reference material, pharmaceutical secondary standard

PHR2868

Fluorouracil Related Compound F, certified reference material, pharmaceutical secondary standard

Pictogrammes

Skull and crossbonesHealth hazard
GHS06,GHS08

Mention d'avertissement

Danger

Mentions de danger

H301,H351

Classification des risques

Acute Tox. 3 Oral - Carc. 2

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 2

1 of 2

5-Fluorouracil for synthesis

Sigma-Aldrich

8.18505

5-Fluorouracil

Uracile United States Pharmacopeia (USP) Reference Standard

USP

1705753

Uracile

S López-Estévez et al.
Gene therapy, 21(7), 673-681 (2014-05-09)
Suicide gene therapy (SGT) is a promising strategy for treating cancer. In this work, we show that thymidine phosphorylase (TP) deficiency, the underlying genetic defect in mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), presents an opportunity to apply SGT using capecitabine, a commonly
Tania Diaz et al.
Journal of surgical oncology, 109(7), 676-683 (2014-02-11)
Surgery is the standard treatment for colorectal cancer (CRC), and adjuvant chemotherapy has been shown to be effective in stage III but less so in stage II. We have analyzed the expression of the miR-200 family in tissue samples from
Zhe Guo et al.
Annals of surgical oncology, 21(9), 3069-3076 (2014-04-15)
It is unclear whether hepatic resection (HR) or transarterial chemoembolization (TACE) is associated with better outcomes for patients with hepatocellular carcinoma (HCC) in Barcelona Clinic Liver Cancer (BCLC) stage A. The present study compared survival for patients with BCLC stage
John M L Ebos et al.
EMBO molecular medicine, 6(12), 1561-1576 (2014-11-02)
Thousands of cancer patients are currently in clinical trials evaluating antiangiogenic therapy in the neoadjuvant setting, which is the treatment of localized primary tumors prior to surgical intervention. The rationale is that shrinking a tumor will improve surgical outcomes and
Steven R Alberts et al.
PharmacoEconomics, 32(12), 1231-1243 (2014-08-27)
Prior economic analysis that compared the 12-gene assay to published patterns of care predicted the assay would improve outcomes while lowering medical costs for stage II, T3, mismatch-repair-proficient (MMR-P) colon cancer patients. This study assessed the validity of those findings
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique